References:

1. Joshi M, Metzler M, McCarthy M, et al. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med. 2006;100:1554-1565.
2. Joshi M, Bernstein J, Solomkin J, et al, and Piperacillin/tazobactam Nosocomial Pneumonia Study Group. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. J Antimicrob Chemother. 1999;43:389-397.
3. FDA Drug and Device Product Approvals. Volume 16, number 1, U.S. Dept of Health and Human Services, Center for Drug Evaluation and Research. Published January 1993. http://www.fda.gov/cder/da/ddpa93.pdf. Accessed November 27, 2007.
4. Data on file, Wyeth Pharmaceuticals Inc.
5. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis. 2007;57:207-215.
6. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis. 1999;28:1062-1066.
7. Smith DW. Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy. 1999;19:129S-132S.
8. May AK, Melton SM, McGwin G, et al. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock. 2000;14:259-264.
9. Bradley SJ, Wilson ALT, Allen MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother. 1999;43:261-266.
10. Winston LG, Charlebois ED, Pang S, et al. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control. 2004;32:462-469.
11. Rice LB. Successful interventions for gram-negative resistance to extended-spectrum β-lactam antibiotics. Pharmacotherapy. 1999;19:120S-128S.
12. Patterson JE, Hardin TC, Kelly CA, et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2000;21:455-458.
13. Bantar C, Vesco E, Heft C, et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimicrob Agents Chemother. 2004;48:392-395.
14. Lan C-K, Hsueh P-R, Wong W-W, et al. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum β-lactamase-producing organisms. J Microbiol Immunol Infect. 2003;36:182-186.
15. Tran T, Kupiec TC, Trissel LA. Quality-control analytical methods: particulate matter in injections: what is it and what are the concerns? Int J Pharm Comp. 2006;10:202-204.
16. Nath N, McNeal E, Obenhuber D, et al. Particulate contaminants of intravenous medication and the limits set by USP General Chapter <788>. Pharmacopeial Forum. 2004;30:2272-2280.
17. Particulate Matter in Injections. General Chapter 788. In: United States Pharmacopeia and the National Formulary. Rockville, MD; 1983:1596-1598.
18. Particulate Matter in Injections. General Chapter 788. In: United States Pharmacopeia and the National Formulary. Rockville, MD; 1995:1813-1819.
19. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
20. Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest. 1988;93:318-324.
21. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462-474.
22. Höffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest. 2002;122:2183-2196.
23. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262-268.
24. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39:885-910.

25. Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(suppl 4):S341-S345.
26. Hill DA, Herford T, Parratt D. Antibiotic usage and methicillin-resistant Staphylococcus aureus: an analysis of causality. J Antimicrob Chemother [letter]. 1998;42:676-677.
27. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis. 2002;8:802-807.
28. Paterson DL, Ko W-C, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med. 2004;140:26-32.
29. Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis. 2002;34:499-503.
30. Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000;31:101-106.
31. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin–tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;54:168-172.
32. Dziekan G, Hahn A, Thüne K, et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect. 2000;46:263-270.
33. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49:999-1005.
34. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med. 2002;162:2469-2477.
35. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis. 2003;37:1643-1648.
36. Yip C, Loeb M, Salama S, et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol. 2001;22:572-575.
37. Lepper PM, Grusa E, Reichl H, et al. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2920-2925.
38. O’Connor KA, Kingston M, O’Donovan M, et al. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM. 2004;97:423-429.
39. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36:1433-1437.
40. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162-1171.
41. T.E.S.T. (Tigecycline Evaluation Surveillance Trial). Web site. http://www.testsurveillance.com Accessed October 22, 2008.
42. Obritsch MD, Fish DN, MacLaren R, et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004;48:4606-4610.
43. Gaynes R, Edwards JR, and the National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848-854.
44. Muder RR, Aghababian RV, Loeb MB, et al. Nursing home-acquired pneumonia: an emergency department treatment algorithm. Curr Med Res Opin. 2004;20:1309-1320.
45. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother. 2007;51:1649-1655.
46. Winstanley TG, Wilcox MH, Spencer RC. Effect of pH on antibiotics used to treat anaerobic infection [letter]. J Antimicrob Chemother. 1992;29:594-595.
47. Primaxin® I.V. (imipenem and cilastatin for injection) Prescribing Information, Merck & Co, Inc., Whitehouse Station, NJ.
48. Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect. 2005;6:27-40.
49. Graham DR, Lucasti C, Malafaia O, et al, and the Ertapenem Complicated Skin and Skin Structure Infections Study Group. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460-1468.
50. Siami FS, LaFleur BJ, Siami GA. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs Medical Center. Clin Ther. 2002;24:59-72.
51. Tan JS, Wishnow RM, Talan DA, et al, and the Piperacillin/Tazobactam Skin and Skin Structure Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother. 1993;37:1580-1586.
52. Kastango ES. The ASHP Discussion Guide for USP <797>: Compounding Sterile Preparations. Summary and Implementation of USP Chapter <797>. http://www.ashp.org/s_ashp/docs/files/HACC_797guide.pdf. Accessed February 14, 2007.
53. Joint Commission on Accreditation of Healthcare Organizations. Critical Access Hospital 2006 Medication Management. Standard MM.4.40. http://www.jointcommission.org/NR/rdonlyres/E6504BF2-E51E-4141-8777-E61380C10B91/0/06_cah_ mm.pdf. Accessed February 14, 2007.
54. Bates DW, Cousins DD, Flynn E, et al. Consensus Development Conference statement on the safety of intravenous drug delivery systems: balancing safety and cost. Hosp Pharm. 2000;35:150-155.
55. Witte KW, Eck TA, Vogel DP. Decision analysis applied to the purchase of frozen premixed intravenous admixtures. Am J Hosp Pharm. 1985;42:835-839.

Indications

• Nosocomial pneumonia (moderate to severe) caused by piperacillin-resistant, β-lactamase producing strains of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside.)
• Community-acquired pneumonia (moderate severity only) caused by piperacillin-resistant, β-lactamase producing strains of Haemophilus influenzae
• Appendicitis (complicated by rupture or abscess) and peritonitis caused by piperacillin-resistant, β-lactamase producing strains of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus
• Uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections caused by piperacillin-resistant, β-lactamase producing strains of Staphylococcus aureus
• Infections caused by piperacillin-susceptible organisms for which piperacillin has been shown to be effective are also amenable to ZOSYN treatment due to its piperacillin content. However, before prescribing, please consult the full Prescribing Information
• Postpartum endometritis or pelvic inflammatory disease caused by piperacillin-resistant, β-lactamase producing strains of Escherichia coli

Important Safety Information

• ZOSYN is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or β-lactamase inhibitors
• Careful inquiry should be made concerning previous hypersensitivity reaction, as serious and occasionally fatal anaphylactic/anaphylactoid reactions (including shock) have been reported in patients receiving therapy with penicillins including ZOSYN
• While ZOSYN possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, during prolonged therapy is advisable
• Clostridium difficile–associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ZOSYN, and may range in severity from mild diarrhea to fatal colitis
• The most commonly reported adverse events in clinical trials of ZOSYN (4.5 g every 6 hours) plus an aminoglycoside included diarrhea (17.6%), fever (2.7%), vomiting (2.7%), urinary tract infection (2.7%), and rash (2.3%)
• The most commonly reported adverse events in clinical trials, irrespective of relationship to therapy, included diarrhea (11.3%), headache (7.7%), constipation (7.7%), nausea (6.9%), and insomnia (6.6%)
• Like all β-lactams, ZOSYN is not a suitable agent for strains of methicillin-resistant Staphylococcus. If MRSA or MRSE is suspected, the addition of an appropriate agent such as vancomycin may be warranted
• To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN and other antibacterial drugs, ZOSYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
• Initial presumptive treatment of patients with nosocomial pneumonia should start with ZOSYN at a dosage of 4.5 g every 6 hours plus an aminoglycoside. If P. aeruginosa is not isolated, the aminoglycoside may be discontinued at the discretion of the treating physician

Please see full Prescribing Information.